<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(5)</volume><submitter>Yamaoka T</submitter><journal>Translational lung cancer research</journal><pagination>2178-2183</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7653124</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.</pubmed_title><pmcid>PMC7653124</pmcid><pubmed_authors>Ohmori T</pubmed_authors><pubmed_authors>Tsurutani J</pubmed_authors><pubmed_authors>Sagara H</pubmed_authors><pubmed_authors>Yamaoka T</pubmed_authors></additional><is_claimable>false</is_claimable><name>HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Oct</publication><modification>2025-04-19T23:40:15.239Z</modification><creation>2025-04-19T23:40:15.239Z</creation></dates><accession>S-EPMC7653124</accession><cross_references><pubmed>33209639</pubmed><doi>10.21037/tlcr-20-578</doi></cross_references></HashMap>